Is RebiF Used for MS?
Yes, RebiF (interferon beta-1a) is an FDA-approved treatment for multiple sclerosis (MS). It reduces relapses and delays disability progression in relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.[1]
How Does RebiF Work for MS?
RebiF is a disease-modifying therapy that mimics natural interferon beta. It modulates the immune system to decrease inflammation and prevent attacks on myelin, the protective sheath around nerves damaged in MS.[1][2]
What MS Types Does RebiF Treat?
- Relapsing-remitting MS (most common form).
- Active secondary progressive MS.
- Clinically isolated syndrome (first MS-like episode).
It does not treat primary progressive MS.[1]
Common Dosage and Administration
RebiF comes in prefilled syringes or autoinjectors (22 mcg or 44 mcg doses). Patients self-inject subcutaneously three times weekly. Starting at a lower dose helps reduce flu-like side effects.[1][2]
Side Effects Patients Report
Flu-like symptoms (fever, chills, muscle aches) affect over 60% initially but often lessen. Injection-site reactions, liver enzyme elevations, depression, and blood count changes occur. Rare risks include severe allergic reactions or liver failure. Regular blood tests monitor safety.[1][2]
How Does RebiF Compare to Other MS Drugs?
| Drug | Type | Dosing Frequency | Key Differences from RebiF |
|------|------|------------------|----------------------------|
| Avonex (interferon beta-1a) | Interferon | Weekly IM injection | Similar efficacy; less frequent dosing but more injection pain. |
| Betaseron/Betaferon (interferon beta-1b) | Interferon | Every other day SC | Slightly higher relapse reduction in some trials; more side effects. |
| Copaxone (glatiramer acetate) | Peptide | Daily SC | No flu-like symptoms; targets different immune pathway. |
| Ocrevus (ocrelizumab) | Monoclonal antibody | Twice yearly IV | Stronger for progressive MS; higher infection risk. |
| Kesimpta (ofatumumab) | Monoclonal antibody | Monthly SC | Newer, self-injectable; convenient but pricier. |
RebiF shows 30% relapse reduction vs. placebo in pivotal trials.[1][3]
Who Makes RebiF and What's the Cost?
Merck (formerly EMD Serono in the US) manufactures RebiF. List price is about $8,000-$9,000 monthly without insurance, though patient assistance lowers it for eligible users.[2]
Patent Status and Generic Availability
RebiF's main composition patents expired in the US by 2019, with some formulation patents extending to 2023-2027. No FDA-approved generic yet; biosimilar development is underway but faces litigation. Check DrugPatentWatch.com for latest expiry dates and challenges.[4]
[1]: FDA Label - RebiF (rebif.com/prescribing-information)
[2]: National MS Society - RebiF Overview (nationalmssociety.org)
[3]: Lancet Neurology - Interferon Beta Trials Meta-Analysis (thelancet.com/journals/laneur)
[4]: DrugPatentWatch - RebiF Patents (drugpatentwatch.com/p/tradename/REBIF)